Zhongshan Hengsai Biological Technology Co., Ltd.

Zhongshan Hengsai Biological Technology is a private Chinese biotech company founded in 2022 and based in Guangdong Province. The company focuses on the research and development of immunotherapies, particularly dendritic cell-based vaccines and therapies targeting cancer indications such as nasopharyngeal carcinoma and hematologic malignancies. As of early 2025, its lead program KSD‑101 targets EBV protein for nasopharyngeal carcinoma and is in Phase 1 clinical trials. The company collaborates with academic institutions like Sun Yat-Sen University to advance its pipeline. No commercialized products or late-stage assets are reported yet.